
Cytokinetics Announces Positive Topline Results From Acacia-Hcm, The Pivotal Phase 3 Clinical Trial Of Aficamten In Patients With Non-Obstructive Hypertrophic Cardiomyopathy
May 5 (Reuters) - Cytokinetics Inc (CYTK.O) :
* CYTOKINETICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM ACACIA-HCM, THE PIVOTAL PHASE 3 CLINICAL TRIAL OF AFICAMTEN IN PATIENTS WITH NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
* CYTOKINETICS INC - ACACIA-HCM MEETS DUAL PRIMARY ENDPOINTS IN KCCQ-CSS AND MAXIMAL EXERCISE PERFORMANCE AT WEEK 36
* CYTOKINETICS INC - NO NEW SAFETY SIGNALS IDENTIFIED; COMPLETION RATES SIMILAR FOR AFICAMTEN AND PLACEBO Source text: Further company coverage: (CYTK.O)